Terms: = Kidney tumors AND CBFB, PEBP2B, 865, ENSG00000067955, Q13951 AND Treatment
17 results:
1. Minimally invasive nephron-sparing treatments for T1 renal cell cancer in patients over 75 years: a comparison of outcomes after robot-assisted partial nephrectomy and percutaneous ablation.
Lehrer R; Cornelis F; Bernhard JC; Bigot P; Champy C; Bruyère F; Rouprêt M; Doumerc N; Bensalah CK; Olivier J; Audenet F; Tricard T; Parier B; Durand X; Durand M; Charles T; Branger N; Surlemont L; Xylinas E; Beauval JB; Barral M
Eur Radiol; 2023 Dec; 33(12):8426-8435. PubMed ID: 37466710
[TBL] [Abstract] [Full Text] [Related]
2. Management of metastatic renal cell carcinoma following prior vascular endothelial growth factor-targeted therapy: A real-world retrospective study from Taiwan.
Chung HJ; Chang YH; Huang YH; Lin TP; Wei TC; Lin FJ; Huang HH; Wang HC
J Chin Med Assoc; 2022 Apr; 85(4):438-442. PubMed ID: 35125401
[TBL] [Abstract] [Full Text] [Related]
3. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL
J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic Value of Variant Histology in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Systematic Review and Meta-Analysis.
Mori K; Janisch F; Parizi MK; Mostafaei H; Lysenko I; Kimura S; Enikeev DV; Egawa S; Shariat SF
J Urol; 2020 Jun; 203(6):1075-1084. PubMed ID: 31479406
[TBL] [Abstract] [Full Text] [Related]
5. Examining Public Communication About kidney Cancer on Twitter.
Sedrak MS; Salgia MM; Decat Bergerot C; Ashing-Giwa K; Cotta BN; Adashek JJ; Dizman N; Wong AR; Pal SK; Bergerot PG
JCO Clin Cancer Inform; 2019 Mar; 3():1-6. PubMed ID: 30860867
[TBL] [Abstract] [Full Text] [Related]
6. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.
Bamias A; Karavasilis V; Gavalas N; Tzannis K; Samantas E; Aravantinos G; Koutras A; Gkerzelis I; Kostouros E; Koutsoukos K; Zagouri F; Fountzilas G; Dimopoulos MA
Int J Clin Oncol; 2019 Apr; 24(4):411-419. PubMed ID: 30374686
[TBL] [Abstract] [Full Text] [Related]
7. Age at diagnosis and the surgical management of small renal carcinomas: findings from a cross-sectional population-based study.
White VM; Marco DJT; Bolton D; Papa N; Neale RE; Coory M; Davis ID; Wood S; Giles GG; Jordan SJ
BJU Int; 2018 Nov; 122 Suppl 5():50-61. PubMed ID: 30307688
[TBL] [Abstract] [Full Text] [Related]
8. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.
Castellano D; Maroto JP; Espinosa E; Grande E; Bolós MV; Llinares J; Esteban E; González Del Alba A; Climent MA; Arranz JA; Méndez MJ; Fernández Parra E; Antón-Aparicio L; Bayona C; Gallegos I; Gallardo E; Samaniego L; García Donas J
Expert Opin Drug Saf; 2018 Jun; 17(6):573-579. PubMed ID: 28535693
[TBL] [Abstract] [Full Text] [Related]
9. Irreversible electroporation in locally advanced pancreatic cancer: A call for standardization of energy delivery.
Martin RC; Durham AN; Besselink MG; Iannitti D; Weiss MJ; Wolfgang CL; Huang KW
J Surg Oncol; 2016 Dec; 114(7):865-871. PubMed ID: 27546233
[TBL] [Abstract] [Full Text] [Related]
10. Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation.
Wang J; Papanicolau-Sengos A; Chintala S; Wei L; Liu B; Hu Q; Miles KM; Conroy JM; Glenn ST; Costantini M; Magi-Galluzzi C; Signoretti S; Choueiri T; Gallucci M; Sentinelli S; Fazio VM; Poeta ML; Liu S; Morrison C; Pili R
Oncotarget; 2016 May; 7(21):29901-15. PubMed ID: 27144525
[TBL] [Abstract] [Full Text] [Related]
11. Systematic review and meta-analysis of target terapies for the treatment of metastatic renal cancer.
Durán M; Matheus W; Ferreira U; Clark O
Int Braz J Urol; 2013; 39(6):768-78. PubMed ID: 24456785
[TBL] [Abstract] [Full Text] [Related]
12. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
Kim HR; Park HS; Kwon WS; Lee JH; Tanigawara Y; Lim SM; Kim HS; Shin SJ; Ahn JB; Rha SY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):825-35. PubMed ID: 24013576
[TBL] [Abstract] [Full Text] [Related]
13. D-dimer elevation and paresis predict thromboembolic events during bevacizumab therapy for recurrent malignant glioma.
Misch M; Czabanka M; Dengler J; Stoffels M; Auf G; Vajkoczy P; Stockhammer F
Anticancer Res; 2013 May; 33(5):2093-8. PubMed ID: 23645760
[TBL] [Abstract] [Full Text] [Related]
14. Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Zhang HL; Zhu Y; Wang CF; Yao XD; Zhang SL; Dai B; Shen YJ; Zhu YP; Shi GH; Ye DW
Int J Urol; 2011 Jun; 18(6):422-30. PubMed ID: 21481012
[TBL] [Abstract] [Full Text] [Related]
15. Radiographic size versus surgical size of renal masses: which is the true size of the tumor?
Alicioglu B; Kaplan M; Yurut-Caloglu V; Usta U; Levent S
J BUON; 2009; 14(2):235-8. PubMed ID: 19650172
[TBL] [Abstract] [Full Text] [Related]
16. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.
Green DM; Breslow NE; Beckwith JB; Finklestein JZ; Grundy PE; Thomas PR; Kim T; Shochat SJ; Haase GM; Ritchey ML; Kelalis PP; D'Angio GJ
J Clin Oncol; 1998 Jan; 16(1):237-45. PubMed ID: 9440748
[TBL] [Abstract] [Full Text] [Related]
17. Soluble ectodomain of c-erbB-2 oncoprotein in relation to tumour stage and grade in human renal cell carcinoma.
Rasmuson T; Grankvist K; Ljungberg B
Br J Cancer; 1997; 75(11):1674-7. PubMed ID: 9184185
[TBL] [Abstract] [Full Text] [Related]
